SPX LABS • RESEARCH LIBRARY
CJC-1295 No DAC Research Overview: GHRH Analogue Science, Testing & the DAC Difference
A research-focused guide to CJC-1295 No DAC terminology, growth hormone-releasing hormone signalling, the important distinction between DAC and non-DAC materials, and peptide analytical testing.
CJC-1295 No DAC Research requires unusually careful terminology. CJC-1295 is associated with a family of synthetic peptides derived from growth hormone-releasing hormone research, but the scientific literature commonly cited for CJC-1295 frequently concerns a compound containing a Drug Affinity Complex, or DAC.
Materials marketed within the research sector as CJC-1295 No DAC do not contain that DAC modification and should not automatically be treated as equivalent to the long-acting CJC-1295 compounds investigated in published human studies.
This distinction matters scientifically, analytically and when interpreting research papers.
This article provides scientific and analytical information only. It does not provide dosing, administration or human-use guidance.
What Is CJC-1295 No DAC?
The term CJC-1295 No DAC is widely used in the research-material market for a GHRH-related peptide that does not contain the Drug Affinity Complex modification associated with the long-acting CJC-1295 molecule.
This terminology needs context because “CJC-1295” has historically been used in scientific literature for a specifically modified GHRH analogue designed to interact with circulating albumin.
Removing or omitting the DAC functionality changes an important structural feature of the molecule.
Important Terminology
CJC-1295 with DAC: refers to the albumin-binding, DAC-modified GHRH analogue described in prominent published CJC-1295 research.
CJC-1295 No DAC: is terminology used for a non-DAC GHRH-related research peptide. Published findings from DAC-modified CJC-1295 should not automatically be transferred to this material.
What Does DAC Mean?
DAC stands for Drug Affinity Complex.
The technology was developed to extend the duration of action of certain peptides by enabling covalent interaction with circulating albumin.
Albumin is an abundant protein found in blood plasma. Attaching a peptide to albumin can substantially alter its pharmacokinetic behaviour compared with the corresponding peptide without the albumin-binding modification.
This was a central feature of the original development of CJC-1295.
Why Was the Drug Affinity Complex Developed?
Many peptide hormones have relatively short biological half-lives because they can be rapidly degraded or cleared.
One strategy investigated by peptide researchers has been to associate therapeutic peptides with longer-lived circulating proteins such as albumin.
Research into the Drug Affinity Complex approach examined whether a reactive chemical group could allow a peptide to form a covalent bond with albumin after exposure to biological conditions.
A foundational paper describing this technology can be reviewed here: Drug affinity complex: a novel approach for extending the plasma half-life of peptides.
This research provides important background for understanding why the DAC component of CJC-1295 is not a trivial naming difference.
CJC-1295 With DAC and Albumin Binding
The DAC-modified CJC-1295 investigated in published research was engineered to bind covalently to albumin.
This albumin interaction was intended to extend exposure to the peptide compared with shorter-lived GHRH-related compounds.
Researchers subsequently investigated this long-acting analogue in healthy human subjects.
A frequently cited clinical study reported prolonged increases in growth hormone and IGF-1 following administration of CJC-1295 and described an estimated half-life measured in days rather than minutes.
The study can be reviewed directly here: Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of growth hormone-releasing hormone, in healthy adults.
Crucially, this paper investigated DAC-modified CJC-1295. It should not be presented as direct evidence that a non-DAC research material has the same pharmacokinetic profile.
Why the DAC vs No DAC Difference Matters
Structural modifications can materially change peptide behaviour.
In the case of CJC-1295, the DAC functionality was specifically introduced to create albumin binding and extend peptide exposure.
A non-DAC material therefore lacks the very modification responsible for that particular albumin-binding mechanism.
| Characteristic | CJC-1295 with DAC | CJC-1295 No DAC terminology |
|---|---|---|
| GHRH-related peptide | Yes | Yes |
| Drug Affinity Complex | Present | Absent |
| Designed for covalent albumin binding | Yes | No DAC functionality |
| Prominent human CJC-1295 literature | Directly studied | Should not be assumed equivalent |
| Analytical identity | Must match DAC-modified analyte | Must match non-DAC analyte |
This distinction is one of the most important points when evaluating CJC-1295 research material.
CJC-1295 No DAC and Modified GRF Terminology
Another source of confusion is the use of the term Modified GRF (1-29), often shortened to Mod GRF (1-29), alongside CJC-1295 No DAC terminology in the research-material market.
Native human GHRH contains a longer amino-acid sequence, but substantial biological activity is associated with its N-terminal region. Researchers have therefore investigated shorter GHRH fragments and modified analogues designed to alter stability while retaining receptor activity.
Commercial terminology is not always used consistently across suppliers. For analytical purposes, the precise stated analyte, molecular structure and applicable laboratory documentation are more informative than relying on a familiar product nickname alone.
What Is GHRH?
Growth hormone-releasing hormone, or GHRH, is a hypothalamic peptide involved in regulation of pituitary growth hormone synthesis and secretion.
GHRH binds to the GHRH receptor expressed on pituitary somatotroph cells and activates intracellular signalling pathways associated with growth hormone release.
Modern reviews of the GHRH system describe a much broader field encompassing receptor biology, synthetic agonists, antagonists and experimental analogues.
Researchers can review an overview of the field here: Growth hormone-releasing hormone and its analogues in health and disease.
How GHRH Receptor Signalling Works
The GHRH receptor belongs to the G-protein-coupled receptor family.
Activation of pituitary GHRH receptors is associated with intracellular signalling involving cyclic AMP and pathways involved in growth hormone synthesis and secretion.
GHRH-related ligand → GHRH receptor → intracellular signalling → pituitary GH secretion
This provides the biological background for research into synthetic GHRH analogues.
CJC-1295 No DAC vs Tesamorelin
CJC-1295 No DAC terminology and tesamorelin both sit within the wider field of GHRH-related peptide research, but they should not be treated as the same molecule.
Tesamorelin is a defined synthetic GHRH analogue with extensive clinical literature and a specific pharmaceutical regulatory history.
CJC-1295 No DAC is terminology used in the research-material sector for a non-DAC GHRH-related peptide.
Shared interaction with the broader GHRH system does not make two peptide analogues chemically identical or analytically interchangeable.
Read our Tesamorelin Research Overview for a separate examination of that compound.
CJC-1295 No DAC vs Ipamorelin
The distinction from ipamorelin is different again.
CJC-1295 No DAC terminology relates to the GHRH receptor pathway.
Ipamorelin is a growth hormone secretagogue associated with the GHS-R pathway.
| Research material | General research pathway |
|---|---|
| CJC-1295 No DAC | GHRH-related signalling |
| Tesamorelin | GHRH receptor signalling |
| Ipamorelin | Growth hormone secretagogue / GHS-R signalling |
Our Ipamorelin Research Overview explains the growth hormone secretagogue pathway separately.
Why Scientific Literature Must Match the Correct Molecule
A common research error is to find a study containing a familiar compound name and assume that every similarly named material is equivalent.
For peptide research, researchers should check:
- The precise peptide sequence or stated analyte
- Any chemical modifications
- Whether a conjugate or affinity group is present
- The molecular form investigated
- The experimental model
- The analytical methods used
This is particularly important for CJC-1295 because the presence or absence of DAC is directly relevant to the molecular design.
Analytical Testing of CJC-1295 No DAC
Analytical testing of a CJC-1295 No DAC research material should address the material actually supplied rather than relying on testing performed on DAC-modified CJC-1295.
Relevant analytical questions may include:
- What analyte is identified on the laboratory report?
- Does the report refer to the non-DAC material?
- What chromatographic purity was reported?
- Was quantitative peptide content measured?
- Which batch or sample was tested?
- When was the analysis performed?
- Which laboratory generated the result?
The words “CJC-1295” alone are not sufficient to resolve the DAC distinction.
Why a CJC-1295 DAC COA Cannot Verify CJC-1295 No DAC
This is especially important when reviewing Certificates of Analysis and third-party laboratory reports.
A report for CJC-1295 with DAC should not be attached to a CJC-1295 No DAC product as though it verified the non-DAC material.
The two descriptions refer to materially different analytes.
Even if both reports show high chromatographic purity, a purity percentage cannot correct an identity mismatch.
Correct compound identity comes before purity percentage.
A highly pure sample of the wrong analyte is still the wrong analyte.
CJC-1295 No DAC HPLC Purity
High-performance liquid chromatography can provide useful information about the chromatographic profile of a peptide research material.
A reported HPLC purity percentage generally describes the relative integrated chromatographic signal associated with the principal component under the analytical conditions used.
It does not automatically establish that the principal peak is the intended non-DAC peptide unless appropriate identity evidence supports that conclusion.
It also does not mean that the reported purity percentage represents the proportion of the entire vial mass composed of peptide.
Read our Peptide Purity Guide for a detailed explanation.
CJC-1295 No DAC Identity Testing
Identity testing becomes particularly valuable when closely related peptide variants exist.
Mass-spectrometric analysis can provide molecular mass information useful for supporting the identity of a peptide and distinguishing molecular forms where their expected masses differ.
Chromatographic and mass-spectrometric methods therefore answer complementary analytical questions.
Our HPLC vs LC-MS for Peptide Testing guide explains this distinction in greater detail.
Purity vs Peptide Content
Chromatographic purity and quantitative peptide content are also separate measurements.
Consider a hypothetical CJC-1295 No DAC research material presented nominally as 5mg:
- Nominal presentation: 5mg
- Reported chromatographic purity: 99.1%
- Reported peptide content: 4.9mg
The 99.1% value concerns chromatographic composition under the reported method.
The 4.9mg value concerns quantitatively measured peptide content.
Neither result should be substituted for the other.
See our Peptide COA Guide for further explanation.
Why CJC-1295 No DAC Batch Testing Matters
Analytical results are batch-specific.
A laboratory report from one CJC-related sample should not automatically be applied to another batch, strength or molecular variant.
For CJC-1295 No DAC, good traceability is especially important because it helps establish that the supporting documentation relates to the correct non-DAC material.
Batch-specific documentation should connect the supplied research material, batch reference, analysed sample and applicable analytical report.
Read our Peptide Batch Testing Guide for more information.
Third-Party Testing of CJC-1295 No DAC
Independent laboratory testing can provide useful analytical evidence where the tested sample is reliably connected to the applicable batch and correctly identified as the non-DAC material.
The phrase “third-party tested” does not resolve a mismatched analyte.
Researchers should inspect what the report actually says rather than relying solely on the laboratory logo or a marketing description.
See our Third-Party Peptide Testing Guide for more information.
What a High CJC-1295 No DAC Purity Result Does Not Prove
A high chromatographic purity result provides useful analytical information, but it should not be expanded into characteristics that were not tested.
Unless separately supported by appropriate evidence, it does not establish:
- Sterility
- Endotoxin status
- Microbial contamination status
- Residual solvent levels
- Water content
- Exact quantitative content unless measured
- Pharmaceutical quality
- Medicinal approval
- Clinical effectiveness
- Equivalence to DAC-modified CJC-1295
- Suitability for human or veterinary administration
SPX Labs CJC-1295 No DAC Documentation
SPX Labs treats CJC-1295 No DAC and CJC-1295 with DAC as different research materials for documentation purposes.
An existing analytical report describing CJC-1295 with DAC is therefore not used as the batch report for the SPX Labs CJC-1295 No DAC 5mg product.
The current CJC-1295 No DAC product is intentionally presented without an exact matching batch-specific third-party report rather than attaching the available DAC report to the wrong material.
When matching analytical documentation becomes available, it should be linked to the applicable non-DAC batch rather than retrospectively applying an unrelated result.
Researchers can review currently available records through the SPX Labs COA Library and learn more about the documentation framework through Quality & Testing.
CJC-1295 No DAC Research Frequently Asked Questions
What does CJC-1295 No DAC mean?
CJC-1295 No DAC is terminology used in the research-material sector for a GHRH-related peptide that does not contain the Drug Affinity Complex modification associated with long-acting CJC-1295.
What does DAC stand for?
DAC stands for Drug Affinity Complex, a technology developed to extend peptide exposure through interaction with circulating albumin.
Is CJC-1295 No DAC the same as CJC-1295 with DAC?
No. The DAC-modified molecule contains an additional functional modification designed for albumin binding. The two should not be treated as analytically or pharmacokinetically identical.
Can research on CJC-1295 with DAC be applied to CJC-1295 No DAC?
It can provide useful background about GHRH analogue research and explain the role of the DAC modification, but results specific to the DAC-modified compound should not automatically be presented as direct evidence for a non-DAC material.
Can a CJC-1295 with DAC COA verify CJC-1295 No DAC?
No. A laboratory report for the DAC-modified analyte should not be used as batch verification for a non-DAC product.
Is CJC-1295 No DAC the same as tesamorelin?
No. Both are discussed within GHRH-related research, but they are different peptide structures and should not be treated as interchangeable.
Is CJC-1295 No DAC the same as ipamorelin?
No. CJC-1295 No DAC terminology relates to GHRH analogue research, whereas ipamorelin is a growth hormone secretagogue associated with the GHS-R pathway.
How is CJC-1295 No DAC purity tested?
Chromatographic methods such as HPLC can provide information about peptide purity, while additional analytical techniques can support molecular identity and quantitative content.
Does SPX Labs have a matching CJC-1295 No DAC batch report?
The current product is presented without an exact matching batch-specific third-party report. The available CJC-1295 with DAC analytical documentation is not represented as testing for the No DAC product.
Explore CJC-1295 No DAC Research Material
Researchers can view the SPX Labs CJC-1295 No DAC 5mg research material for product information and currently available documentation.
For related scientific background, read our Tesamorelin Research Overview and Ipamorelin Research Overview to compare the GHRH and growth hormone secretagogue pathways.
For analytical guidance, continue with the Peptide COA Guide, HPLC vs LC-MS Guide, Peptide Purity Guide, Peptide Batch Testing Guide and Third-Party Peptide Testing Guide.
Research & Analytical Information Only
This article is provided for general laboratory, analytical and scientific education. Discussion of CJC-1295 with DAC is included to explain the scientific literature and the distinction between DAC-modified and non-DAC research materials. Findings involving DAC-modified CJC-1295 should not be interpreted as evidence that a CJC-1295 No DAC material has identical pharmacological or pharmacokinetic properties. SPX Labs research materials are supplied strictly for legitimate laboratory research, analytical testing and scientific evaluation and are not supplied for human or veterinary consumption or administration.
SPX Labs — Precision Research. Verified Quality.